{"id":70581,"date":"2023-02-28T16:07:40","date_gmt":"2023-02-28T21:07:40","guid":{"rendered":"https:\/\/hitconsultant.net\/?p=70581"},"modified":"2023-02-28T16:07:43","modified_gmt":"2023-02-28T21:07:43","slug":"tempus-pfizer-partner-to-advance-oncology-therapeutic-development","status":"publish","type":"post","link":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/","title":{"rendered":"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development"},"content":{"rendered":"\n
\"Tempus,<\/figure>\n\n\n\n

What You Should Know:<\/strong><\/p>\n\n\n\n

– Today, the AI-powered<\/a> genetic testing and precision medicine company Tempus<\/a> announced that it has signed a significant strategic agreement with Pfizer<\/a> to more precisely gather insights that will inform novel drug discovery and development in oncology.<\/p>\n\n\n\n

– Through this collaboration, Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology.<\/p>\n\n\n\n

– Pfizer also has access to Tempus\u2019 broad range of capabilities that support therapeutic R&D, to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus\u2019 clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.<\/p>\n","protected":false},"excerpt":{"rendered":"

What You Should Know: – Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology. – Through this collaboration, Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified, … Read More<\/a><\/p>\n","protected":false},"author":81,"featured_media":70576,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[1799,25444],"tags":[3741,2433,2296,3714,2581,2585,2555,3605],"yoast_head":"\nTempus, Pfizer Partner to Advance Oncology Therapeutic Development<\/title>\n<meta name=\"description\" content=\"Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified to power therapeutic development in oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development\" \/>\n<meta property=\"og:description\" content=\"Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified to power therapeutic development in oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-28T21:07:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-28T21:07:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/02\/Tempus-Pfizer-Partner-to-Advance-Oncology-Therapeutic-Development.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fred Pennic\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:site\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fred Pennic\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\"},\"author\":{\"name\":\"Fred Pennic\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c\"},\"headline\":\"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development\",\"datePublished\":\"2023-02-28T21:07:40+00:00\",\"dateModified\":\"2023-02-28T21:07:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\"},\"wordCount\":125,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"keywords\":[\"AI\",\"Artificial Intelligence\",\"Clinical Trial\",\"Drug Discovery\",\"Oncology\",\"Pfizer\",\"Precision Medicine\",\"Tempus\"],\"articleSection\":[\"Digital Health\",\"Life Sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\",\"url\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\",\"name\":\"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/#website\"},\"datePublished\":\"2023-02-28T21:07:40+00:00\",\"dateModified\":\"2023-02-28T21:07:43+00:00\",\"description\":\"Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified to power therapeutic development in oncology.\",\"breadcrumb\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hitconsultant.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Life Sciences\",\"item\":\"https:\/\/hitconsultant.net\/category\/life-sciences\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hitconsultant.net\/#website\",\"url\":\"https:\/\/hitconsultant.net\/\",\"name\":\"\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hitconsultant.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/hitconsultant.net\/#organization\",\"name\":\"HIT Consultant Media\",\"url\":\"https:\/\/hitconsultant.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"contentUrl\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"width\":\"1024\",\"height\":\"772\",\"caption\":\"HIT Consultant Media\"},\"image\":{\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\",\"https:\/\/twitter.com\/hitconsultant\",\"http:\/\/www.linkedin.com\/company\/2489253\",\"https:\/\/www.pinterest.com\/hitconsultant\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c\",\"name\":\"Fred Pennic\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g\",\"caption\":\"Fred Pennic\"},\"description\":\"Fred Pennic is the Founder and Editor-in-Chief of HIT Consultant. Fred is a seasoned health IT strategist with fourteen years of experience in providing advisory services to executive leadership at hospitals and health systems. Some of his previous clients include Mayo Clinic, Stanford Hospital and Health Clinics, Northwell Health, Trinity Health.\",\"sameAs\":[\"https:\/\/hitconsultant.net\"],\"url\":\"https:\/\/hitconsultant.net\/author\/fpennic\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development","description":"Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified to power therapeutic development in oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/","og_locale":"en_US","og_type":"article","og_title":"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development","og_description":"Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified to power therapeutic development in oncology.","og_url":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/","article_publisher":"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","article_published_time":"2023-02-28T21:07:40+00:00","article_modified_time":"2023-02-28T21:07:43+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/02\/Tempus-Pfizer-Partner-to-Advance-Oncology-Therapeutic-Development.jpg","type":"image\/jpeg"}],"author":"Fred Pennic","twitter_card":"summary_large_image","twitter_creator":"@hitconsultant","twitter_site":"@hitconsultant","twitter_misc":{"Written by":"Fred Pennic","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#article","isPartOf":{"@id":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/"},"author":{"name":"Fred Pennic","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c"},"headline":"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development","datePublished":"2023-02-28T21:07:40+00:00","dateModified":"2023-02-28T21:07:43+00:00","mainEntityOfPage":{"@id":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/"},"wordCount":125,"commentCount":0,"publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"keywords":["AI","Artificial Intelligence","Clinical Trial","Drug Discovery","Oncology","Pfizer","Precision Medicine","Tempus"],"articleSection":["Digital Health","Life Sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/","url":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/","name":"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development","isPartOf":{"@id":"https:\/\/hitconsultant.net\/#website"},"datePublished":"2023-02-28T21:07:40+00:00","dateModified":"2023-02-28T21:07:43+00:00","description":"Pfizer has access to Tempus\u2019 AI-enabled platform and its library of de-identified to power therapeutic development in oncology.","breadcrumb":{"@id":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hitconsultant.net\/2023\/02\/28\/tempus-pfizer-partner-to-advance-oncology-therapeutic-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hitconsultant.net\/"},{"@type":"ListItem","position":2,"name":"Life Sciences","item":"https:\/\/hitconsultant.net\/category\/life-sciences\/"},{"@type":"ListItem","position":3,"name":"Tempus, Pfizer Partner to Advance Oncology Therapeutic Development"}]},{"@type":"WebSite","@id":"https:\/\/hitconsultant.net\/#website","url":"https:\/\/hitconsultant.net\/","name":"","description":"","publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hitconsultant.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/hitconsultant.net\/#organization","name":"HIT Consultant Media","url":"https:\/\/hitconsultant.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/","url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","contentUrl":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","width":"1024","height":"772","caption":"HIT Consultant Media"},"image":{"@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","https:\/\/twitter.com\/hitconsultant","http:\/\/www.linkedin.com\/company\/2489253","https:\/\/www.pinterest.com\/hitconsultant\/"]},{"@type":"Person","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/f7eaad30c9c560826bcbdd28d779118c","name":"Fred Pennic","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e1e715257b8b39a7b4aa16e8e0d458ea?s=96&d=mm&r=g","caption":"Fred Pennic"},"description":"Fred Pennic is the Founder and Editor-in-Chief of HIT Consultant. Fred is a seasoned health IT strategist with fourteen years of experience in providing advisory services to executive leadership at hospitals and health systems. Some of his previous clients include Mayo Clinic, Stanford Hospital and Health Clinics, Northwell Health, Trinity Health.","sameAs":["https:\/\/hitconsultant.net"],"url":"https:\/\/hitconsultant.net\/author\/fpennic\/"}]}},"_links":{"self":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/70581"}],"collection":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/users\/81"}],"replies":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/comments?post=70581"}],"version-history":[{"count":0,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/70581\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media\/70576"}],"wp:attachment":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media?parent=70581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/categories?post=70581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/tags?post=70581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}